Abstract:OBJECTIVE: Over-expression of the epidermal growth factor receptor (EGFR) protein, along with gene amplification, is closely associated with recurrent cervical cancer and the disease’s advanced stages. Additionally, it can have a direct impact on the disease’s prognosis. The following are the members of the HER family: (i) EGFR/HER1; (ii) HER2; (iii) HER3; and (iv) HER4. Figure 1 shows its signalling pathway. The synergy between the members facilitates immune escape by tumour cells, which can lead to tolerance to HER inhibitors. A broad HER inhibitor, a pan-HER inhibitor, can irreversibly inhibit a cell membrane’s HER receptors to their ligands, thereby blocking downstream signal-transduction cascades, inhibiting tumour growth, adhesion, invasion, differentiation, and metastasis. As such, pan-HER inhibitors may be an area of interest in treating recurrent or late-stage cervical cancer. MATERIALS AND METHODS: Through a review of HER-family receptors and their molecular mechanism, we can conclude that pan-HER inhibitors do indeed have a positive impact on therapy for recurrent or late-stage cervical cancer patients. RESULTS: This paper reviews the molecular mechanism that underlies receptors within the HER family, current developments in HER inhibitors, and the potential clinical impacts of pan-HER inhibitors in treating recurrent or late-stage cervical cancer. CONCLUSIONS: Pan-HER inhibitors have been shown to improve prognoses for recurrent or late-stage cervical cancer patients. Preclinical studies show promising results, as well as the potential to improve results for recurrent or late-stage cervical cancer patients. Pan-HER inhibitors have also shown synergistic results in clinical and pre-clinical settings when combined with chemotherapy. However, long-term study is required regarding the combination of pan-HER inhibitors with radiotherapy and other targeted inhibitors. The question of whether or not these inhibitors have a more potent effect across the blood-brain barrier when compared to single HER-targeting agents may be an area of interest for future research. This idea will be explored in clinical cervical cancer trials.

Pan-HER-targeted Approach for Cancer Therapy: Mechanisms, Recent Advances and Clinical Prospect

A Pan-Her-targeted Approach for Recurrent or Late-Stage Cervical Cancer Therapy: Mechanisms, Recent Advances, and Clinical Prospects

Development of Egfr Family Small Molecule Inhibitors for Anticancer Intervention: an Overview of Approved Drugs and Clinical Candidates

Progress and Challenge in Development of Biotherapeutics Targeting MET Receptor for Treatment of Advanced Cancer.

HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs

Clinicopathologic features and treatment advances in cancers with HER2 alterations

Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer

Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes

Recent Progress in HER2 Associated Breast Cancer.

Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy

Recent advances in nanoscale targeted therapy of HER2-positive breast cancer

Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement

Advances in Small-Molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-Cancer Agents

Novel Treatment Strategies for Patients with HER2-positive Breast Cancer Who Do Not Benefit from Current Targeted Therapy Drugs.

Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer

Analysis of Different HER‐2 Mutations in Breast Cancer Progression and Drug Resistance

Synthetic routes and clinical application of Small-Molecule HER2 inhibitors for cancer therapy

Research status and progression in anti-angiogenesis therapy for pancreatic cancer

Advances in HER2-Targeted Therapies: From monoclonal antibodies to dual inhibitors developments in cancer treatment

HER2-targeted therapies in cancer: a systematic review

Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2–positive Breast Cancer